We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The Medicines and Healthcare products Regulatory Agency (MHRA) approved a maximum dose of up to 7.2mg per week of semaglutide (Wegovy) on 6 January 2026.
VMD changes to calculation methods ensures figures reflect the way medicines are used.
This note includes the value for money metrics that providers must report on as part of their Annual Accounts reporting and also explains how to calculate the metrics.
Find out the scale rate expenses for accommodation and subsistence paid to employees who travel outside of the UK.
Includes online returns, rates, charging and record keeping
Information on how the voluntary scheme for branded medicines pricing, access and growth (VPAG) is controlling spend on branded medicines in the NHS.
Further support provided for innovative medicines as the rebate rate falls by more than third for 2026.
The Competition and Markets Authority (CMA) investigated the completed acquisition by Lindab International AB of HAS-Vent Holdings Limited.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).